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faction. Both subscale scores and a composite score (CSS) can 
be calculated, with higher scores indicating greater satisfaction.
The OPSAT-Q, Osteoporosis Targeted Quality of Life (OptQoL),
three single-item global measures related to satisfaction, and
demographic questionnaires were self-administered to eligible
women recruited from four US clinics. Participants were diag-
nosed with osteoporosis or osteopenia and currently taking daily
or weekly bisphosphonate treatment. Reproducibility was
assessed via a follow-up questionnaire completed by participants
two-weeks post baseline. Analyses included item and scale per-
formance, internal consistency reliability, reproducibility, and
construct validity. RESULTS: A total of 104 women with a mean
age of 65 years participated. The majority was white (64.4%),
living with someone (74%), and not currently employed
(58.7%). On a scale of 0–100, individual patient subscale scores
ranged from 17 to 100 and CSS scores ranged from 44–100. All
scores showed acceptable internal consistency reliability (Cron-
bach’s a > 0.70) (range 0.72 to 0.89). Reproducibility exceeded
0.70 for all scores except Conﬁdence with Daily Activity (0.62)
and Overall Satisfaction (0.64). Signiﬁcant correlations were
found between the OPSAT-Q subscales and conceptually similar
global measures (p < 0.001). CONCLUSIONS: The ﬁndings
from this study provide evidence of the validity and reliability of
the OPSAT-Q and support the proposed composition of four
subscales and a composite score. They also support the use of
the OPSAT-Q to examine the impact of potentially more conve-
nient bisphosphonate dosing on patient satisfaction.
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REDUCING MORTALITY IN PATIENTS WITH SUBSTANCE
ABUSE AND CHRONIC NON-MALIGNANT PAIN THROUGH A
MULTIDISCIPLINARY OPIOID RENEWAL CLINIC
Sampson JM, Marsh B
VA Medical Center, Gainesville, FL, USA
OBJECTIVE: Is it safe to treat patients with opioids for chronic
non-malignant pain who have histories of substance abuse or
addicition? Mortality rates for substance abusers are three times
the general population rate. There are few outcome studies in
the medical literature. The Opioid Renewal Clinic follows
patients closely with drug testing, laboratory monitoring, and
provides group education with outside speakers. On site drug
counseling is provided to those determined to be in need. A 
full range of consultation services are available. The disciplines
that make up the clinc include Pharmacy, Nursing, Social 
Work, Internal and Addiction Medicine. Disease management
guidelines are incorporated into the structure of the clinic.
METHODS: This was a retrospective age adjusted mortality
study of 250 Primary Care consults over a two-year period to a
multidisciplinary Opioid Renewal Clinic. The most common
reason for consultation was the difﬁcult to manage patient sec-
ondary to substance abuse. The renewal clinic maintains between
80 to 100 patients. Kaplan-Meier survival curves were per-
formed for pain patients on opioids in Primary Care and the
opioid renewal clinic. Key variables were evaluated by regression
analysis. RESULTS: There were six deaths in patients in Primary
Care and two deaths in patients followed in the Renewal Clinic.
The odds ratio of deaths in usual care to clinic is three, or three
times the rate of the Renewal Clinic. Patients were between
40–60 years of age. Deaths due to known cancer, cardiac or liver
disease were excluded. Cancer deaths were predominantly lung,
and assosciated with tobacco use. CONCLUSIONS: A Multi-
disciplinary Opioid Renewal Clinic can reduce short term mor-
tatlity in high risk patients. Further studies are recommended 
to assess long term mortality rates and secondary outcomes 
on cancer prevention, disease management, and control of
depression.
PPN2
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OBJECTIVES: Pain management centers provide the most
appropriate care for pure neuropathic pain. But before consult-
ing such a center, patients often indulge in “medical nomadism”,
thereby incurring substantial additional costs. This study aimed
to describe the medical trajectory and to estimate the direct costs
of a patient sample with pure neuropathic pain (i.e. with no noci-
ceptive component) during the year before their ﬁrst consulta-
tion in a pain management center. METHODS: Retrospective
data collected by patient questionnaires were used for this cross-
sectional study, in which ten pain management centers partici-
pated between January and April, 2004. A total of 116 patients
who gave written consent and were able to answer the ques-
tionnaire were assessed. The economic outcomes were the total
and refunded Direct Medical Consumption (DMC), including 
all costs directly related to the pathology: medical and para-
medical consultations, drugs, other treatments (surgery, nerve
stimulation, etc.), examinations, and hospitalizations. Costs
were determined by medical fees, ofﬁcial drugs and examinations
tariffs, and Diagnosis Related Groups (DRGs). A bootstrap 
technique was used to improve statistical strength. RESULTS:
The total and refunded average cost per patient ranges from
4650 € to 6830 € and from 3500 to 5690 €, depending on 
the hospitalization sector, private or public. The most costly
items are “Hospitalizations” and “other treatments”, represent-
ing 31% and 24% respectively of the total cost in the private 
sector, and 46% and 23% in the public sector. The “drugs” item
only represents 12% in the private and 8% in the public 
sector. CONCLUSION: This study, based mainly on recalled
declarative data, may be subjectively biased. Nonetheless, the
results give a plausible estimation of direct annual costs of 
neuropathic pain management in France before its appropriate
management in a specialized center, a ﬁeld where few data are
available.
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OBJECTIVES: To characterize hospital IV PCA pump and anal-
gesia acquisition, inventory, and logistics for acute postoperative
pain management. METHODS: Data were collected via inter-
views with 13 geographically diverse US hospitals during an
ongoing prospective, multi-center, observational study of IV PCA
for acute postoperative pain management among subjects under-
going total knee or hip replacement or abdominal hysterectomy.
An interim analysis was performed on data from 13 of 32
planned hospitals. RESULTS: Average IV PCA pump inventory
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per hospital is 105 with 81% among three models: Abbott Life-
care 4100 PCA Plus II, Baxter Health care PCA II, and Baxter
Ipump Pain Management System. Average pump life is 7.7 years.
Sixty-nine percent of hospitals use only one pump model.
Approximately 92% of hospitals own most (93%) of their
pumps. The mean and median pump utilization rates are 68%
and 78%, respectively (n = 9 hospitals). Fifty-four percent of hos-
pitals use both pre-ﬁlled reservoirs (PFR) and staff-ﬁlled reser-
voirs (SFR); 31% use only SFR, and 15% use only PFR. For PFR,
69% of hospitals use morphine, 54% use meperidine, 23% use
hydromorphone, and 8% use fentanyl. For SFR, 77% use hydro-
morphone, 39% use fentanyl, 31% use morphine, and 15% use
meperidine. Hospitals store pumps in multiple locations, with
77% storing them in nursing units, 69% in recovery rooms, 54%
in central supply, 23% in operating rooms, and 15% in phar-
macies, adding to the complexity of IV PCA management. Reser-
voirs also are stored in multiple locations, with 100% of
hospitals storing them in nursing units, 85% in recovery rooms,
31% in operating rooms, and 23% in satellite pharmacies.
Transportation of pump and analgesia from storage to patient
takes approximately 5.7 and 7.6 minutes, respectively. CON-
CLUSIONS: The results of this interim analysis suggest hospital
IV PCA pump logistics vary widely and may signiﬁcantly affect
economics of IV PCA.
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Drugs containing Acetaminophen as a single active ingredient are
included in the list of over-the-counter (OTC) drugs allowed to
be sold in non-pharmacy stores in Israel beginning mid-2005. In
an event of severe overdose, Acetaminophen may cause severe
liver damage, which may result death if not treated urgently.
OBJECTIVE: 1) To examine the knowledge and perception of
parents to children and adolescents regarding the safety, adverse
effects and toxicity of Acetaminophen OTC preparations; and
2)To compare this knowledge to scientiﬁc facts from medical lit-
erature and the experience of leading pediatricians and clinical
pharmacologists. METHODS: 1) Interviews of four leading
Pediatricians/Clinical pharmacologists; and 2) A survey of 193
parents, which took place in three emergency pediatric clinics of
“Maccabi Healthcare Services” (HMO) in central Israel and
among non-medical headquarters staff. The answers were
processed using statistical software. Inﬂuences of several demo-
graphic factors on parents’ answers were examined. RESULTS:
In total, 65% of the enrolled parents had the perception that
non-prescription drugs might be harmful if not used properly,
while 55% of them thought that Acetaminophen might be
harmful if not used properly. In the higher education group more
parents thought that Acetaminophen had had adverse effects.
Higher proportion of parents of two or more children felt they
had knew how to use Acetaminophen brands properly compared
to parents of one child. More than 60% of the parents reported
that they usually purchase Acetaminophen brands without a pre-
scription. About 80% read the patient’s insert. CONCLUSIONS:
Enrolled parents perceive Acetaminophen brands to be safer than
the average non-prescription drug, even though it is known that
in an event of over-dosage Acetaminophen is more toxic than
most other non-prescription drugs. More educated parents in the
survey sample were more aware of the dangers of improper use
of Acetaminophen.
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OBJECTIVES: Although isolated case reports have documented
operator programming errors associated with intravenous
patient-controlled analgesia (IV PCA) infusion pumps, no sys-
tematic analysis of IV PCA-associated problems has been per-
formed. The objective of this study was to use the Manufacturer
and User Facility Device Experience (MAUDE) database, a large
publicly available database maintained by the US Food and Drug
Administration (FDA), to characterize the types of problems
associated with the use of IV PCA infusion pumps. METHODS:
We extracted all IV PCA-related MAUDE case reports from
January, 2002 through December, 2003. Reported causes of
events were abstracted and classiﬁed as: possible operator errors
(eg, pump programming errors); possible patient-related events
(eg, patient tampering), possible device-related events (eg, device
malfunctions), possible adverse drug reactions, and indetermi-
nate events (unspeciﬁed causes). RESULTS: We found 2009
unique IV PCA-related reported events. Number of events
increased from 455 in 2002 to 1554 in 2003, although the FDA
instituted no corresponding changes in reporting requirements
or data collection during these two years. Among all IV PCA-
related reports, 79.1% (N = 1590) were possible device-related
events, 6.5% (N = 131) were possible operator errors, 1.2% (N
= 25) possible adverse drug reactions, 0.6% (N = 12) possible
patient-related events, and 12.6% (N = 251) were indeterminate
events. The device manufacturer conﬁrmed 61% of the reported
possible device-related events. CONCLUSIONS: Previously pub-
lished single case reports of problems with IV PCA infusion
pumps highlight operator error. Our analysis of the MAUDE
data suggests, however, that nearly 80% of reported problems
were attributable to possible device-related events. Although
reporting bias may contribute to the high rates of possible device-
related events (ie, operator errors may be reported as device-
related events), more than half of the possible device-related
malfunctions were conﬁrmed upon manufacturer inspection. To
our knowledge, this is the ﬁrst study to use a large, retrospective
database to examine IV PCA-related problems.
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OBJECTIVES: Dose increases during long-term therapy with
strong opioids have often been reported and result from deteri-
oration of the primary disease or from tolerance development.
The purpose of this study was to compare drug utilization 
patterns with regard to dose changes of transdermal (TD) fen-
tanyl and TD buprenorphine in cancer and non-cancer patients.
METHODS: Retrospective analysis of the “IMS Disease 
Analyzer—mediplus” database which provided data from 400
general practices in Germany. An evaluation according to a pre-
vious peer-reviewed study showed that patients on long-term
treatment (three months and longer) with TD fentanyl or TD
buprenorphine had received similar analgesic pre-medication
